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Objective: Cognitive-behavioural therapy (CBT) has proved effective in treating
delusions, both in schizophrenia and delusional disorder (DD). Clinical trials of DD have
mostly compared CBT with either treatment as usual, no treatment, or a wait-list control.
This current study aimed to assess patients with DD who received CBT, compared with an
attention placebo control (APC) group.
Method: Twenty-four individuals with DD were randomly allocated into either CBT or
APC groups for a 24-week treatment period. Patients were diagnosed on the basis of
structured clinical interviews for mental disorders and the Maudsley Assessment of
Delusion Schedule (MADS).
Results: Completers in both groups (n = 11 for CBT; n = 6 for APC) showed clinical
improvement on the MADS dimensions of Strength of Conviction, Insight, Preoccupation,
Systematization, Affect Relating to Belief, Belief Maintenance Factors, and Idiosyncrasy
of Belief.
Conclusion: When compared with APC, CBT produced more impact on the MADS
dimensions for Affect Relating to Belief, Strength of Conviction, and Positive Actions on
Beliefs.
(Can J Psychiatry 2007;52:182–190)
Clinical implications
 Both APC and CBT significantly improved mood and belief parameters associated with
delusions.
 CBT seemed to have a greater impact than APC on Strength of Conviction, Affect Relating to
Belief, and Actions on Belief, but with weak to moderate effect sizes.
 The MADS items were differentially affected by therapy, which confirmed the dimensional
structure of delusional beliefs.
Limitations
 Both groups had a small number of participants.
 There were incomplete measures for some participants.
 The study lacked long-term follow-up.
D
elusional disorder, the contemporary conceptualization
of paranoia, is characterized by the presence of one or
more nonbizarre delusions and the relative absence of associ-
ated psychopathology. Delusions are currently subdivided by
content and involve experiences that can conceivably appear
in real life, such as being malevolently treated (persecutory
type), having a physical disorder (somatic type), being loved
at a distance (erotomanic type), having an unfaithful sexual
partner (jealous type), and possessing inflated worth, power,
identity, or knowledge (grandiose type). Although the exact
relation between delusional belief and acting on delusions is
unclear, antisocial behaviour is likely if the delusion invokes
strong emotion and when it is associated with catastrophe,
persecution, or paranoia.1
The onset of DD may range from age 18 to 80 years, but it typ-
ically presents at age 34 to 45 years.2 Estimates of the inci-
dence and prevalence of DD (0.7 to 3.0/100 000 and 24 to
30/100 000, respectively) support the clinical impression that
delusional disorders are less common than mood disorders or
schizophrenia. DD may affect either sex; the male-to-female
ratio is 0.85. Once established, it is often a chronic and life-
long affliction.3
Clinical consensus continues to support the use of pimozide or
risperidone for the treatment of DD. Manschrek and Khan4
report no difference in effectiveness between first- and
second-generation antipsychotics, but they note that the stud-
ies were mostly small and uncontrolled and that the absence of
double-blind randomized trials might have undermined the
positive results. In contrast, metaanalyses have concluded that
CBT is an effective treatment, either as an adjunct to
pharmacotherapy or as a main intervention. Terrier5 reviewed
20 clinical trials evaluating the efficacy of CBT as an adjunct
to antipsychotic treatment; most of these trials compared CBT
with standard psychiatric care or treatment as usual. A few
studies, however, have compared CBT with supportive coun-
selling or “befriending,” and here, the results are less
convincing (except for hallucinations).5 In a review,
Dickerson notes that CBT is found to be more effective in
comparison with routine care than when it is compared with
other therapies matched for therapist attention.6 Further, most
CBT packages contain a mix of CBT with more general cop-
ing and social skills training coupled with self-regulation of
emotional states.7
In comparison with studies evaluating CBT for psychosis,
there have been very few clinical trials of CBT for patients
with DD. This subgroup has been considered even more diffi-
cult to treat than schizophrenia patients because of DD
patients’ less evident negative symptoms, more mono-
symptomatic profile, and potentially high functioning. Sharp
et al8 suggest that changing convictions in DD may be particu-
larly difficult because the delusion is the principal symptom,
whereas in schizophrenia, the negative impact of other symp-
toms may emphasize the dysfunctional nature of the delu-
sional component. The current consensus9 is that CBT for
delusions comprises 3 main stages: preparation of the patient
for therapy, cognitive challenge to the conviction, and reality
testing, at which point the patient actively seeks to disconfirm
the conviction. Chadwick and Lowe10 found that a combina-
tion of verbal challenge and reality testing effectively reduced
the level of convictions in 10 out of 12 patients over a 6-month
period. They suggested that, even though reality testing alone
can have an effect on some participants, it was ineffective in 2
cases, and they also suggest that reality testing is more effec-
tive if preceded by verbal challenge. As part of a wider CBT
management program in patients with psychosis, Garety et
al11 administered a CBT program to modify delusions over an
average of 16 sessions during a 6-month period and found a
significant reduction in delusional conviction, general
symptomatology, and depression in 13 participants. Sharp et
al8 applied CBT techniques similar to those of Chadwick and
Lowe10 in a purely DD group (persecutory type) and found
improvement in the conviction of only 3 patients. Currently,
no standard treatment exists for DD, with most clinicians
advocating an idiopathic case-formulation approach. So far,
all treatment trials of CBT for DD have been small in scale or
single case studies; in particular, no trials treating DD exclu-
sively have compared CBT with an equivalent attention treat-
ment rather than no treatment or routine care.
Objective
The present study aimed to evaluate the contribution of a CBT
tailored to DD, compared with an APC. The principal hypoth-
esis was that dimensions of delusional belief and associated
distress would show greater improvement following CBT
than following APC.
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Abbreviations used in this article
ANOVA analysis of variance
APC attention placebo control
BABS Brown Assessment of Beliefs Scale
BAI Beck Anxiety Inventory
BDI Beck Depression Inventory
CBT cognitive-behavioural therapy
DD delusional disorder
MADS Maudsley Assessment of Delusions Schedule
MANOVA multivariate analysis of variance
SD standard deviation
Method
Participants
A total of 32 participants were referred through specialists in
the treatment of psychotic and delusional disorders as well as
through other clinicians who had agreed to refer patients. The
patients were subsequently diagnosed according to DSM-IV
criteria by an experienced psychiatrist (or one of his residents)
and by a trained, independent evaluator who used a
semistructured interview. All participants signed a consent
form approved by the hospital and research centre ethics
committee.
Inclusion–Exclusion Criteria. Participants were recruited
from the Quebec population and diagnosed with DD accord-
ing to the DSM-IV’s main diagnostic criterion for the dis-
order: nonbizarre delusions of at least 1 month’s duration.
Criteria for schizophrenia had never been met (tactile and
olfactory hallucinations may be present in DD if they are
related to the delusional theme). Apart from the impact or
ramifications of the delusion(s), functioning was not mark-
edly impaired and behaviour was not obviously odd or
bizarre. If mood episodes occurred concurrently with delu-
sions, their total duration was brief relative to the duration of
the delusional periods. The disturbance was not due to a gen-
eral medical condition or the direct physiological effects of a
substance (for example, a medication or drug of abuse). We
included only those with DD who had no other psychotic or
other major problems on Axes I and II. As medication is the
current treatment of choice, 15 of the completers were stabi-
lized on medication by the treating psychiatrist. The criterion
of stabilization was no change in symptoms over the preced-
ing 2-month period. All medication was kept constant over the
treatment period. The participants were then asked to read and
sign a consent form outlining the rationale of the study, the
regularity of the therapist meetings, the implications for the
participant in terms of homework and self-monitoring, and the
right of the individual to withdraw at any time. The study was
ethically approved by the local hospital ethics committee. All
participants received or were offered a medical treatment of
choice so that all willing participants received an intervention
of accepted efficacy. The recruitment covered all subtypes of
DD, but most participants were of the persecutory subtype,
which was in accordance with this subtype’s higher preva-
lence rate.
Diagnostic Instruments
To complete differential diagnosis, patients were also
assessed with the Structured Clinical Interview for DSM Axis
1 disorders12 by a trained, independent clinical rater. In addi-
tion, all participants were evaluated, pre- and posttreatment,
with the MADS1 as well as the BABS.15 Participants also kept
a daily diary measuring mood, conviction, and preoccupation.
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Figure 1 The Consort E flowchart
Treatment Protocols
Patients who were stabilized on medication and met the inclu-
sion criteria were randomly allocated to either a CBT program
or an APC condition. The random allocation was made by
consecutive referral at point of entry into the study. Both
groups completed baseline clinical measures. The CBT and
APC consisted of individualized weekly meetings with 1 of 3
licensed psychologists specialized in CBT for DD. The CBT
program was based on programs reported in the literature10,11
and followed the main stages of preparation, cognitive chal-
lenge, and reality testing. In the APC treatment, the therapist
and patient discussed any immediate problems and recurrent
themes in a nondirective and supportive manner, encapsulat-
ing the proper supportive psychotherapeutic approach to the
paranoia patient of interested, attentive, relaxed, and unaf-
fected attitude with an unfeigned air of detachment and sus-
pended judgment, which has been shown to lead to some
remission of symptoms.13 Both programs were manualized
for the therapist.
The APC controlled for time, number of therapeutic encoun-
ters, and nonspecific supportive effects of therapy. The
weekly APC encounters also permitted verification and col-
lection of the daily diary and the administration of other
weekly and monthly clinical assessment measures during the
control period. All patients met with the therapist for 4 prelim-
inary sessions in which the program was explained and the
feasibility of the individual’s participation was established.
The 2 treatment conditions were presented in an identical
manner that emphasized the nature of the research project and
its study of beliefs, the opportunity to discuss distress or trou-
ble related to beliefs, the psychological nature of the interven-
tion, and the interchange and collaboration with the therapist.
Both groups received active treatment or control treatment for
24 weeks. This period was chosen to be consistent with the
treatment period recommended in the literature and concurs
with the treatment period needed for significant clinical
change in our pilot series.14
Clinical Measures
The MADS is a 53-item, clinician-rated research instrument
for the elicitation of the detailed phenomenology of a delu-
sion. It is divided into 8 dimensions and explicitly provides for
a multidimensional assessment. Dimensions assessed include
Strength of Conviction, Belief Maintenance, Affect Related
to Belief, Action on Beliefs, Idiosyncrasy of Belief, Preoccu-
pation With Belief, Systematization of Belief, and Insight.
The MADS authors emphasize the importance of retaining the
distinct aspects of the dimension1 to build a complete clinical
picture. All items retained in the final version of the MADS
achieved a kappa value that exceeded 0.6, with a mean value
of 0.82. The test–retest reliability of the schedule was assessed
with ratings at Time 2 being completed 3 to 5 days after Time
1. The mean kappa value for the test items at test–retest was
0.63. These comparatively modest test–retest agreement lev-
els were thought to most likely reflect true changes in patients’
mental status from Time 1 to Time 2, as opposed to reflecting
the unreliability of the measure.
The BABS was developed to rate the degree of conviction and
insight patients have concerning their beliefs. It consists of 7
items; the first 6 items are added to obtain the total BABS
score. Each item is rated from 0 to 4 (from least to most
severe). The instrument is semistructured. Interrater and
test–retest reliability for individual item scores and total score
are excellent, with a high degree of internal consistency. The
scale correctly classified 90% of 20 participants as delusional
or nondelusional and had a sensitivity of 100% and specificity
of 86%. The scale is sensitive to change.15
Strength of conviction for the principal delusional belief was
rated from 0 to 100 by the participant on a daily basis in a spe-
cially prepared booklet.
The main outcome measure was the MADS rating; this test
was administered by an evaluator independent of the study.
The BABS administered by the therapist and the level of con-
viction recorded in the patients’ daily diaries served only as
checks on the reliability of delusional content and conviction
level of the principal delusional belief.
Questionnaire Measures
Clients also completed a battery of pre- and posttherapy ques-
tionnaires, including the BDI,16 BAI,17 and the Social
Self-Esteem Inventory.18 These measures were administered
pre- and posttreatment and served as additional information to
support interpretation of the main outcome variables.
Treatment Refusers and Abandons
Any patient not completing pretreatment assessment was con-
sidered a refuser, and any patient desisting after the initial
assessment but before treatment was also considered a
refuser. Subsequent discontinuations were considered aban-
dons. Of 32 individuals, 3 were excluded after assessment and
5 withdrew. After meeting the entry criteria, the remaining 24
patients were randomly allocated to either the APC or CBT
groups at the initial assessment. Subsequently, 4 abandoned
prior to the first therapy session and 4 during therapy. Reasons
for abandon varied and included difficulty attending, other
life stresses, worsening of condition, referral to another
agency or health professional, or reversal of decision to partic-
ipate. However, the clinical and demographic profile of refus-
ers did not differ from the completer sample. During
treatment, there were only 4 abandons (2 APC, 2 CBT, 17%),
which is comparable to attrition rates for other CBT applica-
tions. Two participants abandoned after 5 sessions and a third
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participant abandoned after 9 sessions. No further data were
recovered. A fourth participant abandoned after 4 months, and
here, available endpoint evaluations were carried forward to
posttreatment. Clinical and demographic data on a maximum
of 17 completers (n = 11 for CBT; n = 6 for APC) are given in
Table 1.
Treatment Integrity
Therapists were trained by the principal author and followed
through a series of pilot cases to ensure consistent treatment
delivery. All weekly therapy meetings were audio-recorded,
and 30% were randomly selected for monitoring of treatment
integrity by 2 experienced CBT clinicians who were inde-
pendent of the study. Overall, 83% of sessions were catego-
rized accurately as APC or CBT, with a mean confidence level
of 87% and interrater agreement of 79%.
Main Outcome Analysis
The 8 dimensions of the MADS are typically separated to
respect their distinction.1 The MADS items were initially
grouped into 6 coherent groupings that represented, respec-
tively, the dimensions of Belief Maintenance (all 8 items in
MADS Section 2), Affect Relating to Belief (MADS Section
3 and “idiosyncratic emotion”), Positive Actions on Beliefs
(first 12 items in MADS Section 4), Negative Actions on
Beliefs (last 8 items in MADS Section 4), Idiosyncrasy of
Belief (all 3 items in MADS Section 5), and Insight (first 2
items in MADS Section 8 [8.01, “accepting uniqueness of
belief,” and 8.02, “able to think of evidence disproving
belief”]).
To establish an overall treatment effect, the average of all
items within each of these 6 groupings was subjected to
MANOVA. Subsequent to a significant effect, ANOVAs
were independently conducted on the items within each cate-
gory. Analyses used SPSS version 14.02 software (SPSS Inc,
Chicago [IL]; 2006). Responses of “unapplicable” and “don’t
know” (coded 9) were eliminated.
For those participants where this was completed, the daily
diary and the BABS gave supplementary information on the
reliability of MADS belief parameters. Separate ANOVAs
were calculated for the questionnaire measures. Effect sizes
(partial eta-squared: weak = 0.17, medium = 0.24, strong =
0.51, very strong = +0.70) and power estimates are given for
principal significant results.
Results
Five dimensions showed a significant (P < 0.05) overall main
treatment or group-by-treatment effect: Dimension 2,
group-by-treatment effect F1,12 = 3.15, P < 0.05, effect size
0.21, power 0.37; Dimension 3, group-by-treatment effect
F1,12 = 3.54, P < 0.04, effect size 0.23, power 0.41; Dimension
4, treatment effect (F1,13 = 3.27, P < 0.04, effect size 0.20,
power 0.39); Dimension 5, treatment effect F1,13 = 9.20, P <
0.005, effect size 0.41, power 0.80; Dimension 8, treatment
effect F1,12 = 3.52, P < 0.04, effect size 0.23, power 0.41. Neg-
ative Actions on Beliefs was not significant and therefore was
not further explored. Dimensions and key items showing sig-
nificant treatment effects are listed in Table 2. The 2 measures
of Strength of Conviction (MADS Section 1) were analyzed
independently, as were the single items in Dimension 6 (Pre-
occupation with Belief) and Dimension 7 (Systematization of
Belief).
As shown in Table 2, the MADS pre- and posttreatment score
for each dimension were considered separately for group dif-
ferences. Numbers in parentheses refer to the MADS dimen-
sion item numbers. There were no significant departures from
equality of covariance (Box’s test). There were no baseline
differences in patient characteristics between groups.
Intercorrelations at baseline between the BABS (Item 1) and
the MADS clinician-rated “strength of belief” (Item 1.01),
made by the therapist and the independent evaluator,
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Table 1 Demographic, clinical, and medication data
for completers in CBT and APC groups
CBT (n = 11) APC (n = 6)
Age, years: mean (SD) 40 (9.39) 36.83 (13.48)
Education, years: mean (SD) 12.73 (3.58) 12 (1.26)
Sex
Women, %
Men, %
55
45
33.3
66.7
Civil status
Divorced, %
Married, %
Single, %
Widow, %
9
27
55
9
16.7
16.7
66.7
—
Medication
Citalopram, %
Venlafaxine, %
Amitriptyline, %
Risperidone, %
Clonazepam, %
Quetiapine, %
Diazepam, %
Olanzapine, %
Sertraline, %
9
9
9
27
9
9
9
27
—
16.7
—
—
33.3
33.3
16.7
—
16.7
16.7
Diagnostic subtype
Persecutory, %
Other, %
9
2
4
2
respectively, were positive (r = 0.50, P < 0.08).
Intercorrelations between the subjective rating of strength of
belief in the daily diary and the MADS subjective rating of
“strength of belief” were also positive (r = 0.65, P < 0.04). The
concordance between measures of delusional conviction sup-
ported the validity of the MADS measure of conviction.
Subsequent to a significant overall MANOVA, measures
were subjected separately to ANOVA repeated measures.
Significant effects are reported 1-tailed, at P < 0.05, where
hypotheses predicted the direction of significant difference.
Strength of conviction in the principal delusional belief was
measured by a subjective rating of strength of conviction,
rated as a percentage (0 to 100) by the individual, and by the
clinician-rated MADS item (1.01) “certainty of conviction” (0
to 4). Subjective strength of conviction showed a treatment
effect (F1,14 = 15.01, P < 0.001, effect size 0.52, power 0.95)
and an interaction effect (F1,14 = 2.70, P < 0.03, effect size
0.16, power 0.33). Both groups showed a decrease in subjec-
tive strength of conviction but the CBT group showed a mar-
ginally greater decrease. The MADS clinician-rated item
“certainty of conviction” showed a large treatment effect
(F1,13 = 11.88, P < 0.002, effect size 0.48, power 0.89) but no
interaction effect, indicating a decrease in conviction in both
groups over time.
Results for the Belief Maintenance Factors dimension were
affected posttreatment. Both groups reported an equal
posttreatment decrease in “number of recent events in the last
week confirming the belief” (Item 2.02) (F1,13 = 6.43, P <
0.02, effect size 0.33, power 0.65) and “events confirming the
belief since formation” (Item 2.01) (F1,13 = 2.89, P < 0.05,
effect size 0.18, power 0.35). However, both item 207 (“the
possibility of being mistaken”) and item 208 (“reaction to
hypothetical contradiction”), separately rated 0 to 3 (see Table
2), showed a group interaction trend (P < 0.08), with only the
CBT group showing positive change.
Mood change varied between groups. Both groups reported a
tendency to feel less depressed (Item 3.02) (F1,13 = 2.89, P <
0.05, effect size 0.18, power 0.35), but the CBT group only
showed a decrease in idiosyncratic emotion (Item 3.06)
(F1,12 = 4.12, P < 0.03, effect size 0.26, power 0.46).
Results for the Positive Action on Beliefs dimension differed
between groups. Both groups felt able to speak less about the
belief (Item 4.01, “have you told anyone about your belief”)
(F1,13 = 12.00, P < 0.004, effect size 0.48, power 0.89). The
CBT group showed a significant increase in “acting against
the belief” (Item 4.03), whereas the APC group showed a
decrease, thus yielding an interaction (F1,10 = 3.83, P < 0.04,
effect size 0.28, power 0.42). The CBT group also reacted less
strongly to the belief and lost their temper less often (Item
4.05) (F1,13 = 2.91, P = 0.05, effect size 0.18, power 0.54). The
CBT group showed significantly greater reduction in “harm
attempted due to belief” (Item 4.10) than the APC group
(F1,13 = 4.95, P < 0.02, effect size 0.28, power 0.54). Similarly,
for the Idiosyncracy of Beliefs dimension, both groups
reported having fewer disputes about their beliefs (Item 5.03
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Table 2 MADS dimensions and items showing significant pre- and posttreatment effects for CBT and APC
groups
CBT APC
MADS dimensions and key items
Pre
Mean (SD)
Post
Mean (SD)
Pre
Mean (SD)
Post
Mean (SD)
Dimension 1 Strength of Conviction (0–100)a
Item 1.01 “Strength of belief” (0–4)b
Dimension 2 Belief Maintenance (0–1)a
Item 2.08 “Reaction to hypothetical contradiction” (0–3)
Dimension 3 Affect Relating to Belief (0–1)a
Dimension 4 Positive Actions on Belief (0–2)b
Dimension 5 Idiosyncrasy of Belief (0–4)b
Dimension 6 Preoccupation With Belief (0–4)b
Dimension 7 Systematization of Belief (0–3)b
Dimension 8 Insight (0–2)b
94.1 (8.0)
3.5 (0.5)
0.7 (0.2)
2.2 (0.9)
0.8 (0.2)
0.7 (0.2)
1.4 (0.5)
2.6 (0.5)
2.6 (0.5)
1.4 (0.6)
54.6 (33.0)
2.0 (1.5)
0.6 (0.2)
1.4 (1.1)
0.5 (0.2)
0.4 (0.2)
0. 9 (0.6)
1.7 (1.0)
1.5 (1.2)
0.9 (0.8)
82.0 (24.9)
3.4 (0.9)
0.6 (0.3)
1.6 (0.9)
0.6 (0.1)
0.7 (0.3)
1.5 (0.8)
2.4 (0.9)
2.4 (0.9)
1.2 (0.8)
66.0 (34.4)
2.6 (1.3)
0.7 (0.3)
2.0 (1.2)
0.6 (0.2)
0.5 (0.2)
1.1 (0.6)
2.2 (0.8)
2.0 (1.0)
0.9 (0.7)
aSignificant group-by-treatment effect indicating greater change in CBT group
bSignificant overall posttreatment change regardless of treatment modality
“do you have arguments about your beliefs”) (F1,13 = 15.72,
P < 0.002, effect size 0.55, power 0.96).
Both groups reported a posttreatment decrease in “preoccupa-
tion with belief” (Item 6.01) (F1,13 = 6.77, P < 0.01, effect size
0.34, power 0.67) and a decrease in “systematization of delu-
sional beliefs” (Item 7.01) (F1,12 = 5.73, P < 0.02, effect size
0.32, power 0.60).
Questionnaires (Table 3)
BAI scores decreased significantly in both groups (F1,8 = 4.96,
P < 0.03, effect size 0.38, power 0.50). The BDI showed a
treatment effect (F1,4 = 8.31, P < 0.03, effect size 0.68, power
0.59) and a group-by-treatment effect (F1,4 = 11.31, P < 0.02,
effect size 0.74, power 0.71), indicating greater post-CBT
decrease. Social self-esteem increased in the CBT group but
decreased in the APC group, yielding a group-by-treatment
trend (F1,7 = 3.53, P < 0.05, effect size 0.33, power 0.37).
Discussion
There was a significant posttreatment change in several belief
dimensions for both the APC and CBT groups, including
Strength of Belief, Preoccupation With Belief, Systematiza-
tion of Belief, Affect Relating to the Belief, and Idiosyncrasy
of Belief. The most significant change in both groups lay in an
increased ability to control actions and communications
related to the belief. However, in accordance with expecta-
tions, the benefit of CBT was supported by significant
group-by-treatment interaction effects for the following
items: “subjective strength of conviction,” “idiosyncratic dis-
tress,” “reactions to beliefs,” and “stopping acting on beliefs.”
Available questionnaire data supported the clinical outcome
findings (see Table 3), with CBT showing improved out-
comes on depression and self-esteem.
Previous studies have reported on improvements unique to
CBT but also have stated that these benefits are sometimes
minimal when compared with other active psychological
treatments.12 Clinical outcome status in the present study was
categorized according to degree and type of improvement on
the MADS subscales, and the current results also support a
low (0.16) to medium (0.28) effect size between APC and
CBT (depending on the measure). These results provided
posterior power (á = .05) of between 0.30 and 0.60 for the
main hypothesized (between-treatment) effect, whereas the
much stronger main treatment effect size of 0.3 to 0.6 yielded
power estimates between 0.4 and 0.95, regardless of interven-
tion modality. Since the clinical outcome measures are con-
cordant, the results are clearly robust. The posttreatment
decrease in the “strength of belief” parameters was 40% in
CBT and 28% in APC. Neither therapy succeeded overall in
reducing the Strength of Conviction score to zero. However,
in one patient treated with CBT, the item “strength of belief”
dropped to zero, and in 2 others, Preoccupation With Belief
score dropped to zero. The changes in questionnaire results
showed robust effect sizes, particularly for those measuring
depression and self-esteem, even though data were only avail-
able on a smaller number of completers. The low-to-moderate
effect sizes for comparisons between the CBT and APC may
be due to large individual variation in response to treatment
among participants. Alternatively, establishing a strong posi-
tive rapport can affect scores on Insight, Preoccupation With
Belief, and Affect Relating to Belief.1 In contrast to hallucina-
tions, a minimum of directive intervention in the form of
befriending, social support or supportive counselling, and
unstructured treatments may influence delusions.5
The relations among low mood, preoccupation, and strength
of belief remains in debate, but it is clear that some beliefs may
be triggered or accentuated by low mood or higher levels of
anxiety.19 Hence alleviating distress may diminish preoccupa-
tion of belief. However, there were greater benefits to both
mood and cognitive factors with CBT; further, the CBT group
showed a greater change in the cognitive components that are
active in maintenance of DD (that is, ability to challenge
belief, modify strength of belief, and act against the belief).
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Table 3 Pre- and posttreatment questionnaire data for CBT and APC groups
CBT APC
Questionnaires
Pre
Mean (SD)
Post
Mean (SD)
Pre
Mean (SD)
Post
Mean (SD)
BAIa
BDIb
Social Self-Esteem Inventoryb
23.9 (11.7)
25.0 (15.0)
123.2 (21.3)
16.1 (14.6)
12.0 (14.4)
132.5 (24.2)
20.7 (5.1)
17.3 (3.8)
113.3 (28.9)
14.0 (14.2)
18.3 (7.8)
102.0 (22.5)
aSignificant overall change posttreatment regardless of treatment modality
bSignificant group-by-treatment effect indicating greater change in CBT group
The low dropout rate for patients, once they were in the pro-
gram, suggests that the clinical challenge in DD is to over-
come treatment refusal rather than to ensure treatment
compliance. The low abandon rate also confirms and high-
lights the important role of initial preparation and the estab-
lishment of rapport. However, this necessity amplifies the role
of what might be considered nonspecific factors for any more
targeted treatment.
By definition, patients with DD do not usually think that their
delusions are in error. Individuals with DD, however, are usu-
ally willing to discuss their delusional beliefs if they feel they
have found a confidential and sympathetic ear.20 It seems
crucial to initially adopt an accommodating and non-
confrontational approach. Alford and Beck21 suggest that, in
allowing the patient free rein to talk, the therapist can gradu-
ally make the link between external stressors, emotion, and
beliefs, leading to a joint exploration of alternative explana-
tions for certain beliefs. A study by Chadwick and Lowe,10
preparatory interviews lasting from 6 to 12 sessions were
spent with each individual before the delusions were
challenged. This long listening period allowed the relation-
ship to grow before intervention began, which possibly
limited psychological resistance and reduced dropout rates.
Bentall and collaborators22 suggest initially trying to modify
the valence of beliefs (that is, the emotion attached to the
beliefs) rather than their content. Garety and collaborators11
suggest initial use of general cognitive-behavioural strategies
to equip the individual to cope with immediate stresses and
thus initiate the individual into adaptive ways of managing
distress.
The high refusal rate and low completer rate of the current
study evidently impose a limitation on its external validity,
except that such limitations seem unavoidably characteristic
of this study population. The current findings clearly require
replication and extension, but given the paucity of random-
ized controlled trials in this area, these findings do provide
insights into the impact of interventions on separate belief
parameters in DD. In particular, the difference between the
strong main effect of treatment, regardless of modality, in
comparison with the weak-to-moderate effect of CBT, com-
pared with APC, suggests the importance of comparing CBT
with other active conditions in future studies that explore the
efficacy of cognitive-behavioural intervention for treating
delusions.
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Résumé : Traiter le trouble délirant : une comparaison de la thérapie
cognitivo-comportementale avec un groupe témoin attention placebo
Objectif : La thérapie cognitivo-comportementale (TCC) s’est révélée efficace pour traiter les
délires, tant dans la schizophrénie que dans le trouble délirant (TD). Les essais cliniques sur le TD
ont pour la plupart comparé la TCC avec soit un traitement habituel, soit aucun traitement, soit un
groupe témoin de liste d’attente. La présente étude vise à évaluer les patients souffrant de TD qui
ont reçu une TCC comparativement à un groupe témoin attention placebo (TAP).
Méthode : Vingt-quatre personnes souffrant de TD ont été réparties au hasard en groupes de TCC
ou TAP pour un traitement d’une durée de 24 semaines. Les patients ont été diagnostiqués d’après
des entrevues cliniques structurées pour les troubles mentaux et l’échelle d’évaluation du délire de
Maudsley (MADS).
Résultats : Les finissants des deux groupes (11 TCC, 6 TAP) ont démontré une amélioration
clinique aux dimensions suivantes de la MADS : Force de conviction, Intuition, Préoccupation,
Systématisation, Affect relié aux croyances, Facteurs de maintien des croyances et Idiosyncrasie des
croyances.
Conclusion : Comparée avec le TAP, la TCC a produit plus d’effet aux dimensions Affect relié aux
croyances, Force de conviction et Actions positives de la MADS.
